Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

AMSTERDAM, The Netherlands, October 21, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. The decision was made contrary to the positive recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, and the Committee for Advanced Therapies (CAT), which provides guidance on advanced therapeutics such as gene and cell therapy. These expert groups after extensive review and analysis of the data advised the CHMP that Glybera should be approved now under exceptional circumstances. The CHMP Rapporteurs, SAG and the CAT concluded that data from three Glybera clinical trials demonstrated meaningful evidence of clinical efficacy, without any major safety concerns. However, the CHMP is not bound to follow this advice. While AMT carefully reviews the grounds of the CHMP refusal, the Company will focus on strategic advancement of other promising projects in its development pipeline.

"The decision from the CHMP is disappointing particularly because a treatment will now not be available to European patients who suffer from LPLD for whom Glybera is the only therapeutic option. We are encouraged by the validation provided by the CHMP Rapporteurs, Scientific Advisory Group and the Committee for Advanced Therapies regarding our gene therapy platform, indicating that safety is not an issue," said Jörn Aldag, CEO of AMT. "We are evaluating thoroughly and expediently the next steps available to the Company and will provide an update on the future developments of our validated gene therapy pipeline."

On Tuesday October 25, 2011 at 10:00 AM CET, AMT will provide an update on
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Sterlitech is proud to announce that it ... stable of products . These additional products increase ... membrane filters with surface charges. , “We ... our membrane process testing equipment, and correspondingly, a wider ... explains Sterlitech President Mark Spatz. “The addition of ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
... Plexus Corp. (Nasdaq: PLXS ) announced today ... automated screening system for the pre-processing of human papillomavirus (HPV) ... to a current manual process, through sophisticated robotic motions. ... HPV; a virus that has an established link to cervical ...
... general health and self-care management by using simple tools ... May 28 Roche, the maker of ACCU-CHEK(R) blood ... availability of two new tools that can help patients ... impact on their blood glucose levels, giving them greater ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
Cached Biology Technology:Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 2Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 3SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... America,s 27th Annual Mouse Molecular Genetics Conference from ... Grove, California. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the Genetics Society ...
(Date:8/28/2014)... delivering compounds that could positively impact the ... be possible, thanks to researchers in Penn ... vaginal suppository made from the seaweed-derived food ... drug Tenofovir provides a woman-initiated, drug-delivery vehicle ... sexually transmitted infections during unprotected heterosexual intercourse, ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... scientists from the National Human Genome Research Institute (NHGRI), ... reported it has identified six more genetic variants involved ... number of genetic risk factors associated with increased risk ... by the new study had previously been suspected of ...
... crosses between nerve cells. Changes in the strength of ... both memory formation and learning, and help determine how ... Dubnau, Ph.D., leads a CSHL neuroscience lab that studies ... team had previously identified a group of fly genes ...
... -Oceanic shark populations worldwide are declining from destructive high-seas ... shark products (mainly fins and meat), with some shark ... recovering, according to a comprehensive new book co-edited by ... ( www.pewoceanscience.org ), published by Blackwell Publishing, and being ...
Cached Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists identify a mechanism that helps fruit flies lock-in memories 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 3Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 4
...
...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: